title: Early and late effects of hyperbaric oxygen treatment on oxidative stress parameters in diabetic patients.
abstract: Exposure to hyperbaric oxygen leads to increased amount of reactive oxygen species (ROS) that are derived from various sources. After the discovery that ROS can function as signaling molecules, the idea of ROS being hazardous to biological tissues has been challenged. The aim of this study was to examine the changes in oxidative stress parameters in diabetics undergoing hyperbaric oxygen therapy (HBOT) due to foot ulcers. Twenty patients, who received HBOT for diabetic foot ulcers, were included in the study. Blood samples were taken before HBOT and 30 min after exit from the chamber, on the day of the first and the fifteenth HBOT sessions. They were used for the determinations of malondialdehyde (MDA), 8-isoprostane and advanced oxidation protein products (AOPPs). 8-Isoprostane and AOPP levels were not altered significantly after the first HBOT session, while both were increased on the fifteenth day (p<0.05). MDA was significantly increased only after the first HBOT session, and remained unchanged on the fifteenth day (within-day variations). Plasma AOPP levels were lowered significantly after fifteen consecutive HBOT sessions (between-day variations). Decreased AOPP levels suggest that increased oxygenation of tissues due to HBO therapy may activate some endogenous factors that prevent hazardous effects of the disease itself.
authors.affiliation: Department of Biochemistry, Istanbul Faculty of Medicine, Istanbul University, Capa, Istanbul, Turkey. figur@istanbul.edu.tr
authors.forename: F
authors.initials: F
authors.lastname: Gürdöl
authors.forename: M
authors.initials: M
authors.lastname: Cimşit
authors.forename: Y
authors.initials: Y
authors.lastname: Oner-Iyidoğan
authors.forename: S
authors.initials: S
authors.lastname: Körpinar
authors.forename: S
authors.initials: S
authors.lastname: Yalçinkaya
authors.forename: H
authors.initials: H
authors.lastname: Koçak
mesh_terms: D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000378:metabolism; D015415:Biomarkers / Q000097:blood; D001798:Blood Proteins / Q000032:analysis / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D017719:Diabetic Foot / Q000097:blood / Q000628:therapy*; D015237:Dinoprost / Q000031:analogs & derivatives / Q000097:blood; D005260:Female; D006801:Humans; D006931:Hyperbaric Oxygenation / Q000379:methods; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged; D010084:Oxidation-Reduction; D018384:Oxidative Stress / Q000502:physiology*; D017382:Reactive Oxygen Species / Q000097:blood; D016896:Treatment Outcome
chemical_list: D000975:Antioxidants; D015415:Biomarkers; D001798:Blood Proteins; D017382:Reactive Oxygen Species; C075750:8-epi-prostaglandin F2alpha; D008315:Malondialdehyde; D015237:Dinoprost